Abstract
INTRODUCTION
The Group of Eight (G8) is a forum for the governments of eight nations of the
northern hemisphere: Canada, France, Germany, Italy, Japan, Russia, UK and the
US. Together, the G8 countries represent about 65% of Gross World Product.
This report contains easily comparable data on market value, volume,
segmentation and market share for the G8 countries' OTC Pharmaceuticals
markets, plus full fiveyear market forecasts. It examines future problems,
innovations and potential growth areas within the market.
What is this report about?
This report is a part of Datamonitor' s G8 Industry Guide series, which
includes comprehensive category data and analysis across all major industry
sectors. These incisive reports include key data points, charts and expert
analysis on a global, regional and country basis.
Who is the target reader?
This report should make essential reading for anyone involved in the OTC
Pharmaceuticals market, plus anyone considering expansion into the OTC
Pharmaceuticals market, or targeting customers or suppliers in the market.
This report should be read by competitive analysts, distribution managers,
marketing managers, strategic planners and senior executives.
How to use this report
This introductory section sets out the report style and explains the
definitions used in the following chapters: chapter two gives an overview;
chapters three to ten consider G8 countries; and chapter eleven is an appendix
that details Datamonitor' s research methodology.
Table of Contents
CHAPTER 1 INTRODUCTION
- 1.1 What is this report about?
- 1.2 Who is the target reader?
- 1.3 How to use this report
- 1.4 Definitions
CHAPTER 2 GROUP OF EIGHT (G8) OTC
- PHARMACEUTICALS INDUSTRY OUTLOOK
CHAPTER 3 OTC PHARMACEUTICALS IN CANADA
- 3.1 Market Overview
- 3.2 Market Value
- 3.3 Market Segmentation I
- 3.4 Market Segmentation II
- 3.5 Market Share
- 3.6 Five Forces Analysis
- 3.7 Leading Companies
- 3.8 Distribution
- 3.9 Market Forecasts
- 3.10 Macroeconomic Indicators
CHAPTER 4 OTC PHARMACEUTICALS IN FRANCE
- 4.1 Market Overview
- 4.2 Market Value
- 4.3 Market Segmentation I
- 4.4 Market Segmentation II
- 4.5 Market Share
- 4.6 Five Forces Analysis
- 4.7 Leading Companies
- 4.8 Distribution
- 4.9 Market Forecasts
- 4.10 Macroeconomic Indicators
CHAPTER 5 OTC PHARMACEUTICALS IN GERMANY
- 5.1 Market Overview
- 5.2 Market Value
- 5.3 Market Segmentation I
- 5.4 Market Segmentation II
- 5.5 Market Share
- 5.6 Five Forces Analysis
- 5.7 Leading Companies
- 5.8 Distribution
- 5.9 Market Forecasts
- 5.10 Macroeconomic Indicators
CHAPTER 6 OTC PHARMACEUTICALS IN ITALY
- 6.1 Market Overview
- 6.2 Market Value
- 6.3 Market Segmentation I
- 6.4 Market Segmentation II
- 6.5 Market Share
- 6.6 Five Forces Analysis
- 6.7 Leading Companies
- 6.8 Distribution
- 6.9 Market Forecasts
- 6.10 Macroeconomic Indicators
CHAPTER 7 OTC PHARMACEUTICALS IN JAPAN
- 7.1 Market Overview
- 7.2 Market Value
- 7.3 Market Segmentation I
- 7.4 Market Segmentation II
- 7.5 Market Share
- 7.6 Five Forces Analysis
- 7.7 Leading Companies
- 7.8 Distribution
- 7.9 Market Forecasts
- 7.10 Macroeconomic Indicators
CHAPTER 8 OTC PHARMACEUTICALS IN RUSSIA
- 8.1 Market Overview
- 8.2 Market Value
- 8.3 Market Segmentation I
- 8.4 Market Segmentation II
- 8.5 Market Share
- 8.6 Five Forces Analysis
- 8.7 Leading Companies
- 8.8 Distribution
- 8.9 Market Forecasts
- 8.10 Macroeconomic Indicators
CHAPTER 9 OTC PHARMACEUTICALS IN THE UNITED
- KINGDOM
- 9.1 Market Overview
- 9.2 Market Value
- 9.3 Market Segmentation I
- 9.4 Market Segmentation II
- 9.5 Market Share
- 9.6 Five Forces Analysis
- 9.7 Leading Companies
- 9.8 Distribution
- 9.9 Market Forecasts
- 9.10 Macroeconomic Indicators
CHAPTER 10 OTC PHARMACEUTICALS IN THE UNITED
- STATES
- 10.1 Market Overview
- 10.2 Market Value
- 10.3 Market Segmentation I
- 10.4 Market Segmentation II
- 10.5 Market Share
- 10.6 Five Forces Analysis
- 10.7 Leading Companies
- 10.8 Distribution
- 10.9 Market Forecasts
- 10.10 Macroeconomic Indicators
CHAPTER 11 APPENDIX
- 11.1 Data Research Methodology
LIST OF TABLES
- Table 1: G8 OTC Pharmaceuticals industry, revenue ($ bn), 2004 - 2013
24
- Table 2: G8 OTC Pharmaceuticals industry, revenue by country ($ bn) 2004 -
2008(e) 27
- Table 3: G8 OTC Pharmaceuticals industry forecast, revenue by country ($
bn) 2008 - 2013 29
- Table 4: Canada OTC Pharmaceuticals Market Value: $ billion, 2004- 2008(e)
31
- Table 5: Canada OTC Pharmaceuticals Market Segmentation I: % Share, by
Value, 2008(e) 32
- Table 6: Canada OTC Pharmaceuticals Market Segmentation II: % Share, by
Value, 2008(e) 33
- Table 7: Canada OTC Pharmaceuticals Market Share: % Share, by Value, 2007
34
- Table 8: Key Facts: Pfizer Inc 41
- Table 9: Key Financials: Pfizer Inc 43
- Table 10: Key Facts: GlaxoSmithKline Plc 44
- Table 11: Key Financials: GlaxoSmithKline Plc 47
- Table 12: Key Facts: Jamieson Laboratories 48
- Table 13: Canada OTC Pharmaceuticals Distribution: % Share, by Value,
2008(e) 49
- Table 14: Canada OTC Pharmaceuticals Market Value Forecast: $ billion,
2008-2013 50
- Table 15: Canada Size of Population (million) , 2004- 2008(e) 51
- Table 16: Canada GDP (Constant 2000 Prices, $ billion), 2004- 2008(e)
51
- Table 17: Canada Inflation, 2004- 2008(e) 52
- Table 18: Canada Exchange Rate, 2004- 2008(e) 52
- Table 19: France OTC Pharmaceuticals Market Value: $ billion, 2004-2008(e)
54
- Table 20: France OTC Pharmaceuticals Market Segmentation I: % Share, by
Value, 2008(e) 55
- Table 21: France OTC Pharmaceuticals Market Segmentation II: % Share, by
Value, 2008(e) 56
- Table 22: France OTC Pharmaceuticals Market Share: % Share, by Value, 2007
57
- Table 23: Key Facts: Procter & Gamble Company, The 64
- Table 24: Key Financials: Procter & Gamble Company, The 67
- Table 25: Key Facts: Sanofi-Aventis SA 68
- Table 26: Key Financials: Sanofi-Aventis SA 69
- Table 27: Key Facts: Pfizer Inc 70
- Table 28: Key Financials: Pfizer Inc 72
- Table 29: France OTC Pharmaceuticals Distribution: % Share, by Value,
2008(e) 73
- Table 30: France OTC Pharmaceuticals Market Value Forecast: $ billion,
2008-2013 74
- Table 31: France Size of Population (million) , 2004- 2008(e) 75
- Table 32: France GDP (Constant 2000 Prices, $ billion), 2004- 2008(e)
75
- Table 33: France Inflation, 2004- 2008(e) 76
- Table 34: France Exchange Rate, 2004- 2008(e) 76
- Table 35: Germany OTC Pharmaceuticals Market Value: $ billion, 2004-
2008(e) 78
- Table 36: Germany OTC Pharmaceuticals Market Segmentation I: % Share, by
Value, 2008(e) 79
- Table 37: Germany OTC Pharmaceuticals Market Segmentation II: % Share, by
Value, 2008(e) 80
- Table 38: Germany OTC Pharmaceuticals Market Share: % Share, by Value,
2007 81
- Table 39: Key Facts: Bayer AG 88
- Table 40: Key Financials: Bayer AG 91
- Table 41: Key Facts: Pfizer Inc 92
- Table 42: Key Financials: Pfizer Inc 94
- Table 43: Key Facts: GlaxoSmithKline Plc 95
- Table 44: Key Financials: GlaxoSmithKline Plc 98
- Table 45: Germany OTC Pharmaceuticals Distribution: % Share, by Value,
2008(e) 99
- Table 46: Germany OTC Pharmaceuticals Market Value Forecast: $ billion,
2008-2013100
- Table 47: Germany Size of Population (million) , 2004- 2008(e) 101
- Table 48: Germany GDP (Constant 2000 Prices, $ billion), 2004- 2008(e)
101
- Table 49: Germany Inflation, 2004- 2008(e) 102
- Table 50: Germany Exchange Rate, 2004- 2008(e) 102
- Table 51: Italy OTC Pharmaceuticals Market Value: $ billion, 2004-2008(e)
104
- Table 52: Italy OTC Pharmaceuticals Market Segmentation I: % Share, by
Value, 2008(e)
- Table 53: Italy OTC Pharmaceuticals Market Segmentation II: % Share, by
Value, 2008(e)
- Table 54: Italy OTC Pharmaceuticals Market Share: % Share, by Value, 2007
107
- Table 55: Key Facts: Bayer AG 114
- Table 56: Key Financials: Bayer AG 117
- Table 57: Key Facts: GlaxoSmithKline Plc 118
- Table 58: Key Financials: GlaxoSmithKline Plc 121
- Table 59: Key Facts: Novartis AG 122
- Table 60: Key Financials: Novartis AG 124
- Table 61: Italy OTC Pharmaceuticals Distribution: % Share, by Value,
2008(e) 125
- Table 62: Italy OTC Pharmaceuticals Market Value Forecast: $ billion,
2008-2013 126
- Table 63: Italy Size of Population (million) , 2004- 2008(e) 127
- Table 64: Italy GDP (Constant 2000 Prices, $ billion), 2004- 2008(e)
127
- Table 65: Italy Inflation, 2004- 2008(e) 128
- Table 66: Italy Exchange Rate, 2004- 2008(e) 128
- Table 67: Japan OTC Pharmaceuticals Market Value: $ billion, 2004-2008(e)
130
- Table 68: Japan OTC Pharmaceuticals Market Segmentation I: % Share, by
Value, 2008(e) 131
- Table 69: Japan OTC Pharmaceuticals Market Segmentation II: % Share, by
Value, 2008(e) 132
- Table 70: Japan OTC Pharmaceuticals Market Share: % Share, by Value, 2007
133
- Table 71: Key Facts: Pfizer Inc 140
- Table 72: Key Financials: Pfizer Inc 142
- Table 73: Key Facts: Novartis AG 143
- Table 74: Key Financials: Novartis AG 145
- Table 75: Key Facts: Wyeth 146
- Table 76: Key Financials: Wyeth 148
- Table 77: Japan OTC Pharmaceuticals Distribution: % Share, by Value,
2008(e) 149
- Table 78: Japan OTC Pharmaceuticals Market Value Forecast: $ billion,
2008-2013 150
- Table 79: Japan Size of Population (million) , 2004-2008(e) 151
- Table 80: Japan GDP (Constant 2000 Prices, $ billion), 2004-2008(e)
151
- Table 81: Japan Inflation, 2004-2008(e) 152
- Table 82: Japan Exchange Rate, 2004-2008(e) 152
- Table 83: Russia OTC Pharmaceuticals Market Value: $ billion, 2004-2008(e)
154
- Table 84: Russia OTC Pharmaceuticals Market Segmentation I: % Share, by
Value, 2008(e) 155
- Table 85: Russia OTC Pharmaceuticals Market Segmentation II: % Share, by
Value, 2008(e) 156
- Table 86: Russia OTC Pharmaceuticals Market Share: % Share, by Value, 2007
157
- Table 87: Key Facts: Ranbaxy Laboratories Limited 164
- Table 88: Key Financials: Ranbaxy Laboratories Limited 165
- Table 89: Key Facts: Zentiva NV 166
- Table 90: Key Financials: Zentiva NV 167
- Table 91: Key Facts: KRKA 168
- Table 92: Russia OTC Pharmaceuticals Distribution: % Share, by Value,
2008(e) 170
- Table 93: Russia OTC Pharmaceuticals Market Value Forecast: $ billion,
2008-2013 171
- Table 94: Russia Size of Population (million) , 2004-2008(e) 172
- Table 95: Russia GDP (Constant 2000 Prices, $ billion), 2004-2008(e)
172
- Table 96: Russia Inflation, 2004-2008(e) 173
- Table 97: Russia Exchange Rate, 2004-2008(e) 173
- Table 98: United Kingdom OTC Pharmaceuticals Market Value: $ billion,
2004- 2008(e)
- Table 99: United Kingdom OTC Pharmaceuticals Market Segmentation I: %
Share, by Value, 2008(e) 176
- Table 100: United Kingdom OTC Pharmaceuticals Market Segmentation II: %
Share, by Value, 2008(e) 177
- Table 101: United Kingdom OTC Pharmaceuticals Market Share: % Share, by
Value, 2007
- Table 102: Key Facts: GlaxoSmithKline Plc 185
- Table 103: Key Financials: GlaxoSmithKline Plc 188
- Table 104: Key Facts: Pfizer Inc 189
- Table 105: Key Financials: Pfizer Inc 191
- Table 106: Key Facts: Reckitt Benckiser PLC 192
- Table 107: Key Financials: Reckitt Benckiser PLC 194
- Table 108: United Kingdom OTC Pharmaceuticals Distribution: % Share, by
Value, 2008(e)
- Table 109: United Kingdom OTC Pharmaceuticals Market Value Forecast: $
billion, 2008- 2013 196
- Table 110: United Kingdom Size of Population (million) , 2004-2008(e)
197
- Table 111: United Kingdom GDP (Constant 2000 Prices, $ billion),
2004-2008(e) 197
- Table 112: United Kingdom Inflation, 2004-2008(e) 198
- Table 113: United Kingdom Exchange Rate, 2004-2008(e) 198
- Table 114: United States OTC Pharmaceuticals Market Value: $ billion,
2004-2008(e) 200
- Table 115: United States OTC Pharmaceuticals Market Segmentation I: %
Share, by Value, 2008(e) 201
- Table 116: United States OTC Pharmaceuticals Market Segmentation II: %
Share, by Value, 2008(e) 202
- Table 117: United States OTC Pharmaceuticals Market Share: % Share, by
Value, 2007
- Table 118: Key Facts: Pfizer Inc 211
- Table 119: Key Financials: Pfizer Inc 213
- Table 120: Key Facts: GlaxoSmithKline Plc 214
- Table 121: Key Financials: GlaxoSmithKline Plc 217
- Table 122: Key Facts: Wyeth 218
- Table 123: Key Financials: Wyeth 220
- Table 124: United States OTC Pharmaceuticals Distribution: % Share, by
Value, 2008(e)
- Table 125: United States OTC Pharmaceuticals Market Value Forecast: $
billion, 2008-2013 222
- Table 126: United States Size of Population (million) , 2004- 2008(e)
223
- Table 127: United States GDP (Constant 2000 Prices, $ billion), 2004-
2008(e) 223
- Table 128: United States Inflation, 2004- 2008(e) 223
LIST OF FIGURES
- Figure 1: G8 OTC Pharmaceuticals industry, revenue ($ bn) 2004 - 2013
24
- Figure 2: G8 OTC Pharmaceuticals industry, revenue by country (%) 2008e
25
- Figure 3: G8 OTC Pharmaceuticals industry, revenue by country ($ bn) 2004
- 2008(e) 26
- Figure 4: G8 OTC Pharmaceuticals industry forecast, revenue by country ($
bn) 2008 - 2013 28
- Figure 5: Canada OTC Pharmaceuticals Market Value: $ billion, 2004-
2008(e) 31
- Figure 6: Canada OTC Pharmaceuticals Market Segmentation I: % Share, by
Value, 2008(e) 32
- Figure 7: Canada OTC Pharmaceuticals Market Segmentation II: % Share, by
Value, 2008(e) 33
- Figure 8: Canada OTC Pharmaceuticals Market Share: % Share, by Value, 2007
34
- Figure 9: Forces Driving Competition in the OTC Pharmaceuticals Market in
Canada 35
- Figure 10: Drivers of Buyer Power in the OTC Pharmaceuticals Market in
Canada 36
- Figure 11: Drivers of Supplier Power in the OTC Pharmaceuticals Market in
Canada 37
- Figure 12: Factors Influencing the Likelihood of New Entrants in the OTC
Pharmaceuticals Market in Canada 38
- Figure 13: Factors Influencing the Threat of Substitutes in the OTC
Pharmaceuticals Market in Canada 39
- Figure 14: Drivers of Degree of Rivalry in the OTC Pharmaceuticals Market
in Canada 40
- Figure 15: Revenues & Profitability: Pfizer Inc 43
- Figure 16: Revenues & Profitability: GlaxoSmithKline Plc 47
- Figure 17: Canada OTC Pharmaceuticals Distribution: % Share, by Value,
2008(e) 49
- Figure 18: Canada OTC Pharmaceuticals Market Value Forecast: $ billion,
2008-2013 50
- Figure 19: France OTC Pharmaceuticals Market Value: $ billion,
2004-2008(e) 54
- Figure 20: France OTC Pharmaceuticals Market Segmentation I: % Share, by
Value, 2008(e) 55
- Figure 21: France OTC Pharmaceuticals Market Segmentation II: % Share, by
Value, 2008(e) 56
- Figure 22: France OTC Pharmaceuticals Market Share: % Share, by Value,
2007 57
- Figure 23: Forces Driving Competition in the OTC Pharmaceuticals Market in
France 58
- Figure 24: Drivers of Buyer Power in the OTC Pharmaceuticals Market in
France 59
- Figure 25: Drivers of Supplier Power in the OTC Pharmaceuticals Market in
France 60
- Figure 26: Factors Influencing the Likelihood of New Entrants in the OTC
Pharmaceuticals Market in France 61
- Figure 27: Factors Influencing the Threat of Substitutes in the OTC
Pharmaceuticals Market in France 62
- Figure 28: Drivers of Degree of Rivalry in the OTC Pharmaceuticals Market
in France 63
- Figure 29: Revenues & Profitability: Procter & Gamble Company, The 67
- Figure 30: Revenues & Profitability: Sanofi-Aventis SA 69
- Figure 31: Revenues & Profitability: Pfizer Inc 72
- Figure 32: France OTC Pharmaceuticals Distribution: % Share, by Value,
2008(e) 73
- Figure 33: France OTC Pharmaceuticals Market Value Forecast: $ billion,
2008-2013 74
- Figure 34: Germany OTC Pharmaceuticals Market Value: $ billion, 2004-
2008(e) 78
- Figure 35: Germany OTC Pharmaceuticals Market Segmentation I: % Share, by
Value, 2008(e) 79
- Figure 36: Germany OTC Pharmaceuticals Market Segmentation II: % Share, by
Value, 2008(e) 80
- Figure 37: Germany OTC Pharmaceuticals Market Share: % Share, by Value,
2007 81
- Figure 38: Forces Driving Competition in the OTC Pharmaceuticals Market in
Germany 82
- Figure 39: Drivers of Buyer Power in the OTC Pharmaceuticals Market in
Germany 83
- Figure 40: Drivers of Supplier Power in the OTC Pharmaceuticals Market in
Germany 84
- Figure 41: Factors Influencing the Likelihood of New Entrants in the OTC
Pharmaceuticals Market in Germany 85
- Figure 42: Factors Influencing the Threat of Substitutes in the OTC
Pharmaceuticals Market in Germany 86
- Figure 43: Drivers of Degree of Rivalry in the OTC Pharmaceuticals Market
in Germany 87
- Figure 44: Revenues & Profitability: Bayer AG 91
- Figure 45: Revenues & Profitability: Pfizer Inc 94
- Figure 46: Revenues & Profitability: GlaxoSmithKline Plc 98
- Figure 47: Germany OTC Pharmaceuticals Distribution: % Share, by Value,
2008(e) 99
- Figure 48: Germany OTC Pharmaceuticals Market Value Forecast: $ billion,
2008-2013100
- Figure 49: Italy OTC Pharmaceuticals Market Value: $ billion, 2004-2008(e)
104
- Figure 50: Italy OTC Pharmaceuticals Market Segmentation I: % Share, by
Value, 2008(e)
- Figure 51: Italy OTC Pharmaceuticals Market Segmentation II: % Share, by
Value, 2008(e)
- Figure 52: Italy OTC Pharmaceuticals Market Share: % Share, by Value, 2007
107
- Figure 53: Forces Driving Competition in the OTC Pharmaceuticals Market in
Italy 108
- Figure 54: Drivers of Buyer Power in the OTC Pharmaceuticals Market in
Italy 109
- Figure 55: Drivers of Supplier Power in the OTC Pharmaceuticals Market in
Italy 110
- Figure 56: Factors Influencing the Likelihood of New Entrants in the OTC
Pharmaceuticals Market in Italy 111
- Figure 57: Factors Influencing the Threat of Substitutes in the OTC
Pharmaceuticals Market in Italy 112
- Figure 58: Drivers of Degree of Rivalry in the OTC Pharmaceuticals Market
in Italy 113
- Figure 59: Revenues & Profitability: Bayer AG 117
|
相關報告
|
